|
1）Zhu J, Yu Y, Ulbrich MH, et al. Structural model of the TRPP2/PKD1 C-terminal coiled-coil complex produced by a combined computational and experimental approach. Proc Natl Acad Sci U S A. 2011; 108: 10133-8
|
|
|
|
2）Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 surface localization is stimulated by polycystin-2 and cleavage at the G protein-coupled receptor proteolytic site. Mol Biol Cell. 2010; 21: 4338-48
|
|
|
|
|
|
3）Nagao S, Kugita M, Yoshihara D, et al. Animal models for human polycystic kidney disease. Exp Animals. 2012; 61: 477-88
|
|
|
|
|
|
4）Wang X, Harris PC, Somlo S, et al. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transplant. 2009; 24: 526-34
|
|
|
|
|
|
5）Gattone VH 2nd, Chen NX, Sinders RM, et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol. 2009; 20: 1527-32
|
|
|
|
|
|
6）Chen NX, Moe SM, Eggleston-Gulyas T, et al. Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int. 2011; 80: 612-9
|
|
|
|
|
|
7）Buchholz B, Klanke B, Schley G, et al. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrol Dial Transplant. 2011; 26: 3458-65
|
|
|
|
|
|
8）Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2010; 299: F944-51
|
|
|
|
|
|
9）Spirli C, Morell CM, Locatelli L, et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology. 2012 May 31. [Epub ahead of print]
|
|
|
|
|
|
10）Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006; 17: 2220-7
|
|
|
|
|
|
11）Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003; 9: 1323-6
|
|
|
|
|
|
12）Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005; 16: 846-51
|
|
|
|
|
|
13）Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004; 10: 363-4
|
|
|
|
|
|
14）Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family. Life Sci. 1995; 57: 1249-65
|
|
|
|
|
|
15）Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3', 5'-cyclic monophosphate. Gastroenterology. 2007; 132: 1104-16
|
|
|
|
|
|
16）Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010; 21: 1052-61
|
|
|
|
|
|
17）Tradtrantip L, Sonawane ND, Namkung W, et al. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009 22; 52: 6447-55
|
|
|
|
|
|
18）Snyder DS, Tradtrantip L, Yao C, et al. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem. 2011; 54: 5468-77
|
|
|
|
|
|
19）Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol. 2008; 19: 631-8
|
|
|
|
|
|
20）Dere R, Wilson PD, Sandford RN, et al. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One. 2010; 5: e9239
|
|
|
|
|
|
21）Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 830-40
|
|
|
|
|
|
22）Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 820-9
|
|
|
|
|
|
23）Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol. 2012; 23: 842-53
|
|
|
|
|
|
24）McCarty MF, Barroso-Aranda J, Contreras F. Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease. Med Hypotheses. 2009; 73: 1008-10
|
|
|
|
|
|
25）Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011; 108: 2462-7
|
|
|
|
|
|
26）Sweeney WE Jr., von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008; 19: 1331-41
|
|
|
|
|
|
27）Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011; 301: C522-9
|
|
|
|
|
|
28）Talbot JJ, Shillingford JM, Vasanth S, et al. Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A. 2011; 108: 7985-90
|
|
|
|
|
|
29）Takakura A, Nelson EA, Haque N, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet. 2011; 20: 4143-54
|
|
|
|
|
|
30）Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002; 11(15): 1731-42
|
|
|
|
|
|
31）Raphael KL, Strait KA, Stricklett PK, et al. Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am J Nephrol. 2009; 30: 468-73
|
|
|
|
|
|
32）Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2011; 300: F465-74
|
|
|
|
|
|
33）Nagao S, Yamaguchi T. PPARγ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr Mol Pharmacol. 2011 Nov 24. [Epub ahead of print]
|
|
|
|
|
|
34）Yoshihara D, Kugita M, Yamaguchi T, et al. Global gene expression profiling in PPAR-γ agonist-treated kidneys in an orthologous rat model of human autosomal recessive polycystic kidney disease. PPAR Res. 2012; ID695898: 10pages
|
|
|
|
|
|
35）Dai B, Liu Y, Mei C, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han: SPRD rats. Clin Sci (Lond). 2010; 119: 323-33
|
|
|
|
|
|
36）Liu Y, Dai B, Xu C, et al. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PLoS One. 2011; 6: e28915
|
|
|
|
|
|
37）Sankaran D, Bankovic-Calic N, Ogborn MR, et al. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han: SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol. 2007; 293: F821-30
|
|
|
|
|
|
38）Xu T, Wang NS, Fu LL, et al. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep. 2012; 39: 7743-53
|
|
|
|
|
|
39）Xia S, Li X, Johnson T, et al. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development. 2010; 137: 1075-84
|
|
|
|
|
|
40）Fan LX, Li X, Magenheimer B, et al. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 2012; 81: 76-85
|
|
|
|
|
|
41）Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci U S A. 2009; 106: 21819-24
|
|
|
|
|
|
42）Lee SO, Masyuk T, Splinter P, et al. MicroRN A15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest. 2008; 118: 3714-24
|
|
|
|
|
|
43）Tran U, Zakin L, Schweickert A, et al. The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. Development. 2010; 137: 1107-16
|
|
|
|
|
|
44）Sun H, Li QW, Lv XY, et al. MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep. 2010; 37: 2951-8
|
|
|
|
|
|
45）Piazzon N, Maisonneuve C, Guilleret I, et al. Bicc1links the regulation of cAMP signaling in polycystic kidneys to microRNA-induced gene silencing. J Mol Cell Biol. 2012 Jul 3. [Epub ahead of print]
|
|
|
|
|
|
46）Nishio S, Tian X, Gallagher AR, et al. Loss of oriented cell division does not initiate cyst formation. J Am Soc Nephrol. 2010; 21: 295-302
|
|
|
|
|
|
47）Luyten A, Su X, Gondela S, et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J Am Soc Nephrol. 2010; 21: 1521-32
|
|
|
|
|
|
48）Masyuk TV, Radtke BN, Stroope AJ, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology. 2012; 142: 622-633. e4
|
|
|
|
|
|
49)Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Eng1 J Med. 2012 Nov 3. [Epub ahead of print]
|
|
|
|
|